These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15116050)

  • 1. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?
    Kim RB
    Clin Pharmacol Ther; 2004 May; 75(5):381-5. PubMed ID: 15116050
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
    Lamoureux F; Duflot T;
    Therapie; 2017 Apr; 72(2):257-267. PubMed ID: 28237404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacogenetics of statin therapy: when the body aches, the mind will follow.
    Rossi JS; McLeod HL
    J Am Coll Cardiol; 2009 Oct; 54(17):1617-8. PubMed ID: 19833261
    [No Abstract]   [Full Text] [Related]  

  • 4. Point-Counterpoint: SLCO1B1 Genotyping for Statins.
    Wilke RA; Fanciullo J
    S D Med; 2017 Mar; 70(3):102-104. PubMed ID: 28813770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on efflux and uptake transporters as determinants of statin response.
    Rocha KCE; Pereira BMV; Rodrigues AC
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):613-624. PubMed ID: 29842801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetic analysis can predict adverse effects of statins].
    Garwicz D; Wadelius M
    Lakartidningen; 2013 May 7-21; 110(19-20):951-2. PubMed ID: 23745502
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.
    Fujino H; Nakai D; Nakagomi R; Saito M; Tokui T; Kojima J
    Arzneimittelforschung; 2004; 54(7):382-8. PubMed ID: 15344842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.
    Dou Y; Zhu X; Wang Q; Tian X; Cheng J; Zhang E
    Ann Lab Med; 2015 May; 35(3):329-35. PubMed ID: 25932441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics and drug toxicity.
    Nakamura Y
    N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
    [No Abstract]   [Full Text] [Related]  

  • 10. SLCO1B1 variants and statin-induced myopathy.
    Vladutiu GD; Isackson PJ
    N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.
    Nozawa T; Minami H; Sugiura S; Tsuji A; Tamai I
    Drug Metab Dispos; 2005 Mar; 33(3):434-9. PubMed ID: 15608127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
    Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
    Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
    Arrigoni E; Del Re M; Fidilio L; Fogli S; Danesi R; Di Paolo A
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of the functional expression of the human organic anion transporting polypeptide 1B1 (OATP1B1) and its genetic variant 521T/C in the mouse liver.
    Chae YJ; Lee KR; Lee JH; Lee W; Kim DD; Chung SJ; Maeng HJ
    Eur J Pharm Sci; 2017 Jan; 96():28-36. PubMed ID: 27619346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
    Shitara Y; Sugiyama Y
    Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.
    Niemi M; Pasanen MK; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Oct; 80(4):356-66. PubMed ID: 17015053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics.
    Mwinyi J; Johne A; Bauer S; Roots I; Gerloff T
    Clin Pharmacol Ther; 2004 May; 75(5):415-21. PubMed ID: 15116054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins personalized.
    Superko HR; Momary KM; Li Y
    Med Clin North Am; 2012 Jan; 96(1):123-39. PubMed ID: 22391257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
    Chen C; Mireles RJ; Campbell SD; Lin J; Mills JB; Xu JJ; Smolarek TA
    Drug Metab Dispos; 2005 Apr; 33(4):537-46. PubMed ID: 15616150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.
    Puccetti L; Ciani F; Auteri A
    Atherosclerosis; 2010 Jul; 211(1):28-9. PubMed ID: 20347093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.